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Objectives;  
To assess how type and number of symptoms are related to survival in head 
and neck cancer patients.   
 
Design; Patients were followed-up for over 10 years from the Scottish Audit of 
Head and Neck Cancer; (national cohort of head and neck cancer patients in 
Scotland 1999 – 2001). September 2013, cohort was linked to national 
mortality data. First, second and third presenting symptoms were recorded at 
diagnosis.   
 
Setting; National prospective audit - Scotland 
 
Participants; A subset of 1589 patients, from the original cohort of 1895, who 
had cancer arising from one of the four main subsites; larynx, oropharynx, oral 
cavity and hypopharynx.   
 
Main outcome measures; Median survival in relation to patients’ presenting 
symptoms.  
 
Results; 1146 (72%) males and 443 (28%) females, mean age at diagnosis 
64 years (13 – 95).  There was a significant difference in survival in relation to 
the number of the patient’s presenting symptoms; one symptom had a median 
survival of 5.3 years compared with 1.1 years for three symptoms. Patients 
who presented with weight loss had a median survival of 0.8 years, compared 
to 4.2 years if they did not (p<0.001). Patients who presented with hoarseness 
had a median survival of 5.9 years compared to 2.6 years without (p<0.001).  
There was no significant difference in long term survival for patients who 
presented with an ulcer, compared to those that did not (p=0.105). 
 
Conclusions. 
This study highlights the importance of patients’ presenting symptoms, giving 
valuable information in highlighting appropriate “red flag” symptoms and 
subsequent treatment planning and prognosis.   
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INTRODUCTION 
 
Patients who have head and neck cancer present with symptoms which may 
include hoarseness, dysphagia, pain, neck lump and ulceration. Such “red 
flag symptoms”, are used as the basis for national cancer referral guidelines 
At the time of diagnosis in this cohort of patients, the SIGN guidelines were 
used1-3.   
It has been previously demonstrated, in other subsites, that symptoms can 
help predict prognosis.  Furuta et al demonstrated that patients who had lung 
cancer , and presented with breathlessness and chest pain, had a worse 
prognosis4;  The presence of fever, chills and night sweats have been used 
within lymphoma staging for many years5.  In the 1990’s Piccirillo et al 
highlighted that symptom severity in larynx cancer offered additional 
prognostic information not provided by the TNM classification6. To date there 
have been very few reports on the quantitative assessment of presenting 
symptoms and subsequent survival in head and neck cancer7. 
The Scottish Audit of Head and Neck Cancer (SAHNC) in 1999-2001 
recorded the presenting symptoms of the patients recruited and provides an 
opportunity to assess the long-term survival profile of patients’ symptoms with 
respect to subsite. 
The aim of this study was to assess how the type and number of symptoms 
are related to survival in a large cohort of head and neck cancer patients and 
discuss potential factors.   
 
 
Materials and Methods 
Patients and Data Linkage 
The SAHNC recruited 1895 patients between 1st September 1999 and 31st 
August 2001.  Methods have previously been described 8-11. Data were 
recorded on all new HNC patients diagnosed in Scotland. Quality assurance 
processes were carried out including cross-checking the incident data with 
medical and pathology results. This paper assesses a subset of 1589 
patients, with the index cancer arising from one of the four main subsites; 
larynx, oropharynx, oral cavity and hypopharynx. The cohort was linked to the 
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National Records of Scotland (NRS) mortality data as at 30th September 2013 
by ISD Scotland. Records were linked using the Howard Newcombe principle 
12.  Information governance and data linkage approvals were obtained from 
the NHS Privacy Advisory Committee (now known as the Public Benefits and 
Privacy Panel).  
 
Determinants included in analysis  
Determinants included age, sex, smoking behaviour, alcohol consumption, 
patient performance status, site, Stage, symptoms at presentation and 
treatment modality.  
Symptoms were recorded at the time of diagnosis by the treating clinician, 
with key symptoms being recorded in numerical order, with the patient’s 
principal symptom recorded first.  This was in an ‘open structure basis’ with 
the clinician being able to record up to three symptoms they considered of 
relevance. Each different symptom was given a numerical code for entry into 
the database. There were therefore no suggestions of symptoms to be 
recorded or pre-determined checklist for the treating clinician to use.  
Stage was determined using the Tumour, Node and Metastases (TNM) 
Classification of Malignant Tumours 13, and the cohort was grouped 
accordingly into Stage I/ II/ III/ IV. Anatomical site was classified using the 
International Classification of Disease version 10 14, and the cohort was 
grouped into 4 categories –larynx (C32), oral cavity (C02–C04, C05.0, C06, 
C14), oropharynx (C01, C05.1–, C09, C10), hypopharynx (C12, C13).   
Treatment modality was grouped into five categories: i) surgery only; ii) 
radiotherapy only; iii) surgery combined with radiotherapy; iv) chemotherapy 
only, chemotherapy combined with surgery, chemotherapy combined with 
radiotherapy, and chemotherapy combined with both surgery and 
radiotherapy; and v) no treatment.  
 
Measurement of symptom 
First, second and third presenting symptom were recorded at diagnosis and 
included hoarseness, pain/discomfort, lump in neck, dysphagia, ulceration, 
weight loss, swelling, other/unknown. Variables for the number of symptoms 
each patient had were created, and additional binary “yes/no” variables for 
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each presenting symptom were created. An interaction test confirmed a 
relationship between symptom and anatomical site, and therefore the analysis 
was performed for all patients and each anatomical site (larynx, oral cavity, 
oropharynx and hypopharynx). If the resultant group was small, for example 
hoarseness in oral cancer subgroup, they were placed in ”other/unknown” 
category.  
 
Statistical analysis 
Five-year and 12-year disease-specific survival were calculated using the 
Kaplan-Meier method with 95% confidence intervals (CIs), and the log-rank 
test was used to determine the differences between the survival curves. Age- 
and Stage- adjusted Cox proportional hazard models were used to determine 
the differences in survival with 95% CIs.  
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Results 
 
Patient Demographics 
The study cohort of 1589 included larynx, oral cavity, oropharynx or 
hypopharynx cancer with all other subsites within the head and neck being 
excluded.  The cohort consisted of 1146 (72%) males and 443 (28%) females.  
The mean age was 64 years (13 – 95 years). Table 1 shows the patient 
demographics for the study cohort.  Larynx cancer was the most common 
subsite with 603 patients  (38%), followed by oral cavity with 534 patients 
(34%), oropharynx  with 330 patients (21%), then hypopharynx with 122 
patients (7%).  The majority of patients were current or previous smokers.  
Stage at presentation varied among the subsites, with half of the larynx 
cancer and oral cavity cancer patients presenting with Stage I or II cancer 
whereas two-thirds of the oropharynx and hypopharynx cancer patients 
presented with Stage III or IV disease.   
 
 
Survival  
Table 2 demonstrates the disease specific 5- and 12-year survival for all 
patient variables.  Table 3 demonstrates the median survival for all patient 
variables. There was a significant difference in survival across subsites, with 
larynx patients having 71% 5-year survival and 63% 12-year survival 
compared to hypopharynx patients with 32% 5-year survival and 24% 12-year 
survival.  There was a significant difference in survival at both 5 and 12-years 
depending on how many symptoms a patient presented with.  If only one 
symptom was reported median survival was 5.3 years compared with 1.1 
years for three symptoms. All head and neck cancer patients who presented 
with hoarseness had a significantly (p<0.001) better survival than those who 
did not have hoarseness at both 5 and 12 years, with the median survival of a 
patient presenting with hoarseness being 5.9 years compared to 2.6 years for 
a patient without hoarseness. Patients presenting with a neck lump only had a 
median survival of 1.3 years versus 4.8 years for those without a neck lump at 
presentation.  There was no significant difference in long term survival for 
those patients presenting with an ulcer, compared to those that did not, with 
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median survival being 4.2 years in patients presenting with an ulcer compared 
to 3.5 years for those not presenting with an ulcer. Patients that presented 
with weight loss had a significantly shorter median survival of 0.8 years, 
compared to 4.2 years if they did not have weight loss.  Patients that 
presented with dysphagia had a significantly shorter median survival of 1.3 
years compared to 4.3 years for those that didn’t have dysphagia.   
 
Symptoms 
Table 4 demonstrates a frequency histogram for the number of symptoms and 
type of symptoms present at diagnosis for each subsite.   The most commonly 
presenting symptom for those diagnosed with larynx cancer was hoarseness 
(82%), for oral cavity was ulceration (51.5%); for oropharyngeal cancer was 
pain (60.9%) and for hypopharyngeal cancer was weight loss (23.8%).  
 
Larynx Cancer patients 
Table 5 demonstrates the median survival of patients diagnosed with larynx 
cancer.  Patients who presented with 0-1 symptoms had a median survival of 
7.7 years compared to 1.95 years if they presented with 3 symptoms.  A 
patient with hoarseness who presented with larynx cancer had a median 
survival of 7 years compared to 2.2 years for those who didn’t have 
hoarseness.   
Patients that had weight loss as a presenting symptom had a median survival 
of 1.3 years, which after adjustment for age and Stage in multivariate analysis 
was still a significant factor (p=0.003).  
 
Oral Cavity Cancer Patients 
Table 5 demonstrates the median survival of patients diagnosed with oral 
cavity cancer.  Patients who presented with 1 symptom had a median survival 
of 4.6 years compared to those with 3 symptoms that had a medical survival 
of only one year.  Patients who presented with an ulcer had a median survival 
of 4.9 years compared to only 2.8 years for those who didn’t.  Patients 
presenting with weight loss had a median survival of 0.6 years, compared to 4 
years for those without weight loss.   
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Oropharynx  Cancer Patients 
Table 5 demonstrates the median survival of patients diagnosed with 
oropharyngeal cancer.  Patients who presented with 1 symptom had a 
significantly better median survival of 3.3 years, compared to those with 3 
symptoms who had a median survival of only 1.0 year.  Patients who 
presented with a neck lump had a median survival of 1.8 years compared to 
2.6 years for those without a neck lump.   
 
Hypopharynx Cancer Patients 
Table 5 demonstrates the median survival of patients diagnosed with 
hypopharyngeal cancer.  There was no significant difference in median 
survival by the number of symptoms they presented with: patients with 1 
symptom had the same median survival as patients who presented with 3 
symptoms – 1.1 years.  However, it should be noted that the numbers of 
hypopharynx patients were much smaller than the other subsites.   
 
Age and Stage adjusted analysis. 
Table 6 reports the age and stage adjusted analysis for each symptom and 
subsite.  The number of symptoms a patient presented with was significantly 
related to survival after adjustment for age and stage in larynx, oral cavity and 
oropharynx subsite.  Number of symptoms did not impact on survival for 
hypopharynx patients.  Weight loss was the only symptom that was a 
significant predictor of survival after adjustment for age and stage in all four 
subsites.   
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Discussion 
This prospective series of head and neck cancer patients demonstrates the 
importance of number and type of symptoms at the time of diagnosis.  Red 
flag symptoms may indicate more serious underlying pathology.  Red flag 
symptoms in the NICE guidelines for suspected head and neck cancer include 
hoarseness, neck lump, pain or discomfort and ulceration.  There was a 
significant difference in survival in relation to the number of the patient’s 
presenting symptoms; one symptom had a median survival of 5.3 years 
compared with 1.1 years for three symptoms, which was still significant for the 
subsites of larynx, oral cavity  and oropharynx after adjustment for age and 
stage. Any head and neck cancer patient who presented with hoarseness had 
a median survival of 5.9 years compared to 2.6 years without.  There was no 
significant difference in long term survival for patients who presented with an 
ulcer, compared to those that did not (p=0.105).  Patients presenting with 
dysphagia survived 1.3 years compared to 4.3 years for those that did not.  
Patients who presented with weight loss had a median survival of 0.8 years, 
compared to 4.2 years if they did not (p<0.001), even after adjustment for age 
and stage at all subsites. 
 
Symptoms as a predictor of prognosis 
Cancer symptoms (type, duration, severity) and the performance status of the 
patient are clinical elements that represent the severity of the cancer in the 
patient. Using symptoms as a predictor of prognosis is not a new idea to head 
and neck cancer, however to date symptoms have failed to make it into any 
formal staging system or help direct treatment and predict prognosis. Over 50 
years ago Jackson and Norris discussed the prognostic significance of 
“increasing degrees of dyspnea, stridor, hoarseness and dysphagia, with 
persistent pain on swallowing and progressive cachexia” in a review article 
about laryngeal cancer15. Piccirillo et al highlighted that symptom severity in 
larynx cancer offered additional prognostic information that the TNM 
classification did not have.  It was suggested that the addition of symptoms to 
the Staging provided an index of the biological behaviour of the tumour that 
cannot simply be discerned from anatomy alone.  Our results would support 
this finding, as we found that the number of symptoms a patient presented 
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with was significant for both 5 and 12 year survival, after adjustment for Stage 
and age, in laryngeal, oral cavity and oropharynx cancer. Interestingly there 
was no significance in patients with hypopharyngeal cancer, highlighting the 
very poor prognosis of patients diagnosed with this disease, no matter how 
many symptoms they present with.  However, it should be noted that we did 
have small numbers of hypopharyngeal cancer compared to the other 
subsites.   
Our results also highlight that patients with specific symptoms, and confirmed 
head and neck cancer at a specific subsite, have an added indicator of 
prognosis. In our cohort patients who presented with hoarseness, and 
diagnosed with larynx cancer specifically, had a median survival of 7 years, 
demonstrating the “good” prognosis associated with hoarseness.     In stark 
contrast weight loss was a significant predictor of poor prognosis in all four 
subsites in this series, even after adjustment for age and stage.  The median 
survival for a patient with weight loss was only 0.8 years, the worst median 
survival for all the symptoms examined.  Weight loss has previously been 
shown to be an independent prognostic factor in palliative care patients16.  
The significance of weight loss has been reported previously in patients with 
recurrent oral cavity and oropharyngeal cancer,17  however this is the first 
study in head and neck cancer to highlight its significance in median survival.  
At present the MDT decision making process focuses on the TNM staging of 
the primary tumour.  However, there is now increasing evidence that specific 
types and number of symptoms are of prognostic value.  There is an 
argument for using this information not only in the decision making process in 
treatment planning, but also in informed discussions with patients.  To 
develop this concept a more rigorous approach of symptom recording, using 
an agreed symptom group, reflecting prognosis, could be implemented and 
recorded and the relationship with outcome noted.   
 
Value of Red Flag Symptoms 
One of the difficulties with red flag symptoms in head and neck cancer is that 
there are symptoms which are frequently experienced by many patients who 
have non malignant issues, such as benign pathology or functional conditions.  
In comparison, colorectal cancer has a much stronger evidence base with 
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regards to GPs and presenting symptoms. The higher predictive value of 
symptoms in patients referred for investigation when compared to the 
predictive value on first presentation to primary care demonstrates that the 
GP is able to identify, in part, those patients who are likely to harbour a 
colorectal cancer.  It also demonstrates that if there is a higher relative rise 
from the predictive value in the general population to those presenting to the 
GP that patients are also capable of identifying which symptoms matter for 
colorectal cancer18.  This is certainly not the case for head and neck cancer, 
with many published reports identifying that patients don’t know the risk 
factors and symptoms for head and neck cancer19. 
 
 
 
Red Flags in Head and Neck Cancer  
In 2015 NICE published “Suspected cancer: recognition and referral.”  This 
UK guideline document (NG12)3  offers “evidence based advice on the 
recognition of, and referral for, suspected cancer”.  Despite such guidelines, 
to date there has not been any publication showing an improvement in head 
and neck cancer detection rates20 21. The key questions are therefore: is the 
correct group of symptoms being used, and of these symptoms are they 
sufficiently refined?   
From this study it would appear that the 2015 NICE guidelines have failed to 
address a number of other important “red flag” symptoms that should warrant 
an urgent suspicion of cancer (USOC) referral.   Patients who presented with 
dysphagia, and were subsequently diagnosed with cancer of any subsite, the 
median survival was only 1.4 years, with the survival decreasing to less than a 
year (0.9 yr) if they were diagnosed with hypopharyngeal cancer. Dysphagia 
as a symptom was not present in the 2005 or the 2015 NICE guidelines for 
USOC referrals. Tikka et al highlighted the significant association of 
dysphagia with head and neck cancer and this study adds further evidence to 
the need for this symptom to be included as a “red flag” needing a USOC 
referral.22 The presence of pain in the form of sore throat or otalgia, was 
present as a “red flag” symptom in the 2005 NICE guidelines, but was 
removed in the updated 2015 version.  Pain as a symptom at diagnosis in this 
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series was associated with a 2.3 year median survival, compared to 4.8 years 
median survival for those without pain.  This significant difference in median 
survival would suggest that pain should be reintroduced to the “red flag” 
symptoms requiring urgent referral, a finding also highlighted by Tikka et al22. 
Weight loss is a very common symptom in patients with cancer and is not 
specific to head and neck cancer.  However this study highlights the poor 
prognostic significance of weight loss as a presenting symptom.  Weight loss 
was an independent prognostic factor for survival at all four subsites after 
adjustment for age and stage. Weight loss has not been a “red flag” symptom 
for head and neck cancer in the NICE guidelines of 2005 or 2015, but it may 
be that unexplained weight loss should be considered for inclusion in future 
“red flag” symptoms.   
The second issue is to refine the chosen head and neck red flag symptoms to 
yield a higher proportion of head and neck cancer. Currently patients who  
present with persistent unexplained hoarseness for over three weeks need a 
2 week referral for urgent suspicious of cancer (USOC).  Our study highlights 
that a patient who presents with hoarseness, and is subsequently diagnosed 
with a squamous cell carcinoma of the head and neck, has a median survival 
of 5.9 years; if they are subsequently diagnosed with laryngeal squamous cell 
carcinoma the median survival is 7 years, arguably a very good prognosis. 
Given this prognosis it could be suggested that the referral USOC for 
hoarseness should be voice ‘never normal’ for over six weeks, excluding most 
of the ‘non-structural’ dysphonic patients from the USOC clinics.  
 The “evidence” for the “red flags” in laryngeal and oral cancer was based on 
one publication23, highlighting a significant failing in the development of these 
guidelines.  However, it may be that there simply isn’t the evidence base at 
present to develop true “evidence based “ guidelines and this is an area that 
requires further research.  
 
 
 
Strengths and limitations of the study 
The main limitation of this study was the accuracy of the recording of the 
symptoms.  As this was designed to simply describe the study cohort at 
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diagnosis multiple clinicians were involved and symptom recording was as 
reported by the patient, not based on an interrogation using a pre-determined 
agreed list of symptoms.   Although this potential inaccuracy could be used as 
an argument for not using symptoms as a prognostic tool, compared to an 
“objective” TNM Stage, this could be addressed by using an agreed symptom 
checklist. This is supported by Picirrillo who demonstrated, in a series of 
larynx cancer patients, that symptom staging was just as reliable as the 
anatomical staging6.    
A strength of this study is the large number of patients which were included in 
the original head and neck audit, and furthermore the long term survival data 
which we have in relation to the patients.  Furthermore, the applicability of the 
findings are twofold; firstly it could be used to help direct symptom 
presentation for the early detection of head and neck cancer and secondly 
could be used to help build prognostic models and treatment planning 
discussions with the patient.   
 
 
Conclusion 
This study highlights the value of using patients’ symptoms throughout a 
patient’s journey, from when they first present in primary care with “red flag” 
symptoms to direct urgent referrals, and in specialist cancer units to support 
the diagnosis, treatment planning, prognosis and communication with 
patients. As many symptoms appear to be of prognostic value there is a need 
for more “symptom research” prior to the updating of national guidelines and 
involvement in staging systems.     
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Table 1. Patient demographics by anatomical site.  
  
Larynx 
Frequency 
(n = 603) 
% 
Oral Cavity 
Frequency  
(n = 534) 
% 
Oropharynx 
Frequency 
 (n = 330) 
% 
Hypopharynx 
Frequency  
(n = 122) 
% 
Sex         
Male 485 80.4 345 64.6 232 70.3 84 68.9 
Female 118 19.6 189 35.4 98 29.7 38 31.2 
Age         
<45 14 2.3 31 5.8 22 6.7 2 1.6 
45 – 54 79 13.1 86 16.1 64 19.4 19 15.6 
55 – 64 210 34.8 152 28.5 130 39.4 39 32.0 
65 – 74 199 33.0 149 27.9 77 23.3 43 35.3 
>= 75 101 16.8 116 21.7 37 11.2 19 15.6 
Smoker         
Current 400 66.3 308 57.7 234 70.9 82 67.2 
Previous 164 27.2 112 21.0 53 16.1 26 21.3 
Never 31 5.1 93 17.4 36 10.9 12 9.8 
Not recorded 8 1.3 21 2.9 7 2.1 2 1.6 
Alcohol         
Current (problem) 152 25.2 168 31.5 114 35.6 37 30.3 
Previous (problem) 67 11.1 61 11.4 52 15.8 17 13.9 
Occasional drinker/never drank 287 47.6 256 47.9 140 42.4 60 49.2 
Not recorded 97 16.1 49 9.2 24 7.3 8 6.6 
WHO Status         
Normal activity 279 46.3 231 43.3 129 39.1 37 30.3 
Strenuous activity restricted 161 26.7 133 24.9 93 28.2 45 36.9 
Up and about >50% waking hours 50 8.3 35 6.6 33 10.0 15 12.3 
Confined to bed/chair > 50% waking 
hours 
37 6.1 35 6.6 22 6.7 9 9.4 
Not recorded 79 12.6 100 18.7 53 16.1 16 13.1 
Stage         
I 160 26.5 123 23.0 32 9.7 6 4.9 
II 169 28.0 120 22.5 45 13.6 11 9.0 
III 105 17.4 80 15.0 56 17.0 21 17.2 
IV 157 26.0 160 30.0 188 57.0 82 67.2 
Unknown 12 2.0 51 9.6 9 2.7 2 1.6 
Treatment         
Surgery only 56 9.3 258 48.3 43 13.0 10 8.2 
Radiotherapy only 346 57.4 61 11.4 55 16.7 28 23.0 
Surgery and radiotherapy 166 19.2 140 26.2 99 30.0 28 23.0 
Chemotherapy 49 8.1 34 6.4 95 28.8 40 32.8 
No treatment 36 6.0 41 7.7 38 11.5 16 13.1 
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Table 2. Overall disease specific survival for patient variables at 5 and 12 
years.   
 
  
5-year survival 
percent (95% 
CIs) 
5-year p-value 12-year survival 
percent (95% 
CIs) 
12-year p-value 
Overall  61.4 (58.8, 63.9)  54.1 (51.3, 56.9)  
Age     
Less than 45 80.0 (68.0, 87.9) <0.001 70.0 (57.0, 79.7) <0.001 
45 to 54 68.4 (62.0, 74.0)  60.2 (53.2, 66.4)  
55 to 64 64.3 (59.9, 68.5)  58.4 (53.6, 62.9)  
65 to 74 58.2 (53.2, 63.0)  50.6 (45.0, 56.0)  
75 and over 48.6 (41.9, 54.9)  38.7 (31.0, 46.3)  
Anatomical site     
Larynx 71.2 (67.2, 74.7) <0.001 63.6 (59.1, 67.7) <0.001 
Oral cavity 63.2 (58.6, 67.4)  54.2 (49.2, 59.0)  
Oropharynx 49.1 (43.1, 54.8)  45.1 (39.0, 51.0)  
Hypopharynx 32.9 (23.4, 42.6)  24.1 (15.1, 34.3)  
Stage     
I 90.2 (86.2, 93.1) <0.001 82.7 (77.3, 86.9) <0.001 
II 73.6 (68.4, 78.2)  63.7 (57.4, 69.3)  
III 61.6 (54.9, 67.6)  51.3 (44.1, 58.1)  
IV 38.1 (33.7, 42.4)  33.6 (29.2, 38.1)  
Unknown 44.3 (31.4, 56.5)  37.3 (24.6, 50.1)  
Number       
0-1 symptom 71.4 (69.0, 74.4) <0.001 63.0 (59.1, 66.5) <0.001 
2 symptoms 54.1 (49.3, 58.7)  47.2 (42.0, 52.2)  
3 symptoms 39.9 (33.1, 46.6)  35.5 (28.6, 42.4)  
Hoarseness     
Yes 71.2 (67.1, 74.9) <0.001 63.5 (58.9, 67.7) <0.001 
No 55.7 (52.3, 58.9)  48.5 (44.9, 52.0)  
Pain/discomfort     
Yes 51.6 (47.3, 55.8) <0.001 44.4 (39.8, 48.9) <0.001 
No 67.5 (64.2, 70.5)  60.0 (56.5, 63.4)  
Lump in neck     
Yes 42.6 (34.4, 50.4) <0.001 39.4 (31.2, 47.4) <0.001 
No 63.7 (61.0, 66.3)  55.8 (52.8, 58.7)  
Dysphagia     
Yes 44.4 (37.8, 50.7) <0.001 40.8 (34.1, 47.4) <0.001 
No 64.9 (62.0, 67.5)  56.8 (53.7, 59.8)  
Ulceration     
Yes 65.5 (59.8, 70.6) 0.050 56.7 (50.3, 62.6) 0.105 
No 60.4 (57.4, 63.2)  53.4 (50.2, 56.5)  
Swelling     
Yes 57.6 (48.3, 65.8) 0.206 51.9 (42.3, 60.7) 0.454 
No 61.8 (59.1, 64.4)  54.3 (52.8, 58.9)  
Weight loss     
Yes 26.3 (18.2, 35.1) <0.001 19.3 (10.9, 29.4) <0.001 
No 64.5 (61.8, 67.1)  57.0 (54.1, 59.9)  
Other/unknown     
Yes 51.3 (44.7, 57.4) 0.003 45.1 (38.2, 51.8) 0.002 
No 63.5 (60.7, 66.2)  56.0 (52.8, 58.9)  
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Table 3. Overall Median Survival.   
  
Median survival in days (95% 
CIs) 
Median survival 
in years (95% 
CIs) 
Overall  1321 (1185, 1492) 3.6 (3.2, 4.1) 
Age   
Less than 45 5029 (3278,  13.8 (9.0, 
45 to 54 2646.5 (1834, 3233) 7.2 (5.0, 8.9) 
55 to 64 1602 (1257, 1959) 4.4 (3.4, 5.4) 
65 to 74 1019.5 (828, 1340) 2.8 (2.3, 3.7) 
75 and over 613 (437, 820) 1.7 (1.2, 2.2) 
Anatomical site   
Larynx 2144 (1817, 2448) 8.9 (5.0, 6.7) 
Oral cavity 1357.5 (1113, 1667) 3.7 (3.0, 4.6) 
Oropharynx 836.5 (607, 1052) 2.3 (1.7, 4.6) 
Hypopharynx 387 (317, 501) 1.1 (0.9, 1.4) 
Stage   
I 3815 (3222, 4088) 10.4 (8.8, 11.2) 
II 1926 (1569, 2378) 5.3 (4.3, 6.5) 
III 1295.5 (945, 1760) 3.5 (2.6, 4.8) 
IV 447 (383, 543) 1.2 (1.0, 1.5) 
Unknown 477.5 (293, 964) 1.3 (0.8, 2.6) 
Number   
0-1 symptom 1951 (1715, 2263) 5.3 (4.7, 6.2) 
2 symptoms 960 (730, 1300) 2.6 (2.0, 3.6) 
3 symptoms 413 (353, 586) 1.1 (1.0, 1.6) 
Hoarseness   
Yes 2164 (1864, 2528) 5.9 (5.1, 6.9) 
No 960.5 (822, 1140) 2.6 (2.3, 3.1) 
Pain/discomfort   
Yes 841 (651, 1031) 2.3 (1.8, 2.8) 
No 1745.5 (1418, 1982) 4.8 (3.9, 5.4) 
Lump in neck   
Yes 461 (339, 651) 1.3 (0.9, 1.8) 
No 1485 (1312, 1698) 4.1 (3.6, 4.6) 
Dysphagia   
Yes 486 (383, 690) 1.3 (1.0, 1.9) 
No 1565.5 (1363, 1833) 4.3 (3.7, 5.0) 
Ulceration   
Yes 1523 (1198, 1899) 4.2 (3.3, 5.2) 
No 1295.5 (1084, 1418) 3.5 (3.0, 3.9) 
Swelling   
Yes 1256 (686, 1871) 3.4 (1.8, 5.1) 
No 1333 (1195, 1508) 3.6 (3.3, 4.1) 
Weight loss   
Yes 294 (245, 376) 0.8 (0.7, 1.0) 
No 1537.5 (1341, 1749) 4.2 (3.7, 4.8) 
Other/unknown   
Yes 1006 (841, 1302) 2.8 (2.3, 3.6) 
No 1388.5 (1271, 1665) 3.8 (3.5, 4.6) 
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Table 4. Frequencies of each symptom per anatomical site after grouping for survival analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Larynx 
Frequency 
(n = 603) 
% 
Oral Cavity 
Frequency  
(n = 534) 
 
Oropharynx 
Frequency 
 (n = 330) 
% 
Hypopharynx 
Frequency  
(n = 122) 
% 
Number                 
0-1 symptom 348 57.7 317 59.4 158 47.9 28 23.0 
2 symptoms 170 28.2 165 30.9 104 31.5 57 46.7 
3 symptoms 85 14.1 52 9.7 68 20.6 37 30.3 
Hoarseness                 
Yes 497 82.4 N/A* N/A* 24 7.3 41 33.6 
No 106 17.6 N/A* N/A* 306 92.7 81 66.4 
Pain/discomfort                 
Yes 154 25.5 203 38.0 201 60.9 57 46.7 
No 449 74.5 331 62.0 129 39.1 65 53.3 
Lump in neck                 
Yes 35 5.8 37 6.9 83 25.2 28 23.0 
No 568 94.2 497 93.1 247 74.8 94 77.0 
Dysphagia                 
Yes 97 16.1 45 8.4 77 23.3 64 52.5 
No 506 83.9 489 91.6 253 76.7 58 47.5 
Ulceration                 
Yes N/A* N/A* 275 51.5 54 16.4 N/A* N/A* 
No N/A* N/A* 259 48.5 276 83.6 N/A* N/A* 
Weight loss               
 Yes 44 7.3 27 5.1 39 11.8 29 23.8 
No 559 92.7 507 94.9 291 88.2 93 76.2 
Swelling                 
Yes N/A* N/A* 86 16.1 41 12.4 N/A N/A 
No N/A* N/A* 448 83.9 289 87.6 N/A N/A 
Other/unknown         
Yes 114 18.9 194 36.3 115 34.8 41 33.6 
No 489 81.1 340 63.7 215 65.2 81 66.4 
*Symptom included in “Other/unknown” due to low frequency of patients with the symptom for this  anatomical site 
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Table 5. Median survival for each subsite and symptom.  
 
  Larynx Median Survival in 
years (95% CI) 
 Oral Cavity 
Median Survival in years 
(95% CI) 
 Oropharynx 
Median Survival in years 
(95% CIs) 
 
 Hypopharynx 
Median Survival in years (95% CIs) 
Number         
0-1 symptom  7.7 (6.7, 8.8)  4.6 (3.7, 5.7)  3.3 (2.3, 4.2)  1.1 (0.8, 2.0) 
2 symptoms  4.2 (2.6, 5.8)  3.3 (1.7, 4.6)  2.4 (1.3, 3.9)  1.2 (0.8, 1.8) 
3 symptoms    1.0 (0.6, 2.4)  1.0 (0.7, 1.7)  1.1 (0.7, 1.3) 
Hoarseness         
Yes  7.0 (5.9, 7.9)  NA  1.7 (0.2, 4.8)  1.1 (0.7, 1.7) 
No  2.2 (1.5, 2.8)  NA  2.3 (1.7, 3.0)  1.0 (0.8, 1.4) 
Pain/discomfort         
Yes  2.9 (2.1, 4.8)  2.5 (1.6, 3.6)  2.3 (1.4, 3.2)  1.5 (0.9, 1.8) 
No  6.6 (5.7, 7.8)  4.8 (3.7, 5.7)  2.3 (1.4, 3.6)  0.9 (0.7, 1.3) 
Lump in neck         
Yes  1.7 (0.9, 2.3)  0.9 (0.4, 1.6)  1.8 (0.7, 3.6)  1.2 (0.7, 1.7) 
No  6.0 (5.3, 7.1)  4.1 (3.5, 4.9)  2.6 (1.7, 3.3)  1.0 (0.9, 1.4) 
Dysphagia         
Yes  2.7 (1.4, 4.1)  1.2 (0.5, 2.0)  1.1 (0.7, 2.1)  0.9 (0.8, 1.3) 
No  6.3 (5.6, 7.4)  4.1 (3.5, 4.9)  2.7 (2.1, 3.6)  1.2 (0.9, 1.7) 
Ulceration         
Yes  NA  4.9 (3.7, 6.2)  2.2 (1.2, 3.4)  NA 
No  NA  2.8 (1.9, 3.7)  2.4 (1.6, 3.1)  NA 
Weight loss         
Yes  1.3 (0.7, 2.2)  0.6 (0.2, 1.4)  0.7 (0.4, 1.1)  0.8 (0.5, 0.9) 
No  6.3 (5.4, 7.5)  4.0 (3.5, 4.9)  2.8 (2.2, 3.6)  1.3 (1.0, 1.7) 
Swelling         
Yes  NA  4.5 (2.0, 6.8)  3.1 (1.1, 7.5)  NA 
No  NA  3.7 (2.9, 4.4)  2.3 (1.5, 2.8)  NA 
Other/unknown         
Yes  2.8 (2.4, 5.1)  3.1 (2.0, 4.2)  2.8 (0.9, 4.8)  1.3 (0.5, 1.9) 
No  6.4 (5.4, 7.4)  3.9 (3.1, 5.0)  2.2 (1.5, 2.9)  1.1 (0.8, 1.3) 
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Table 6: Age- and Stage- adjusted hazard ratios for disease-specific survival 
  
Larynx HRs  
(95% CIs) 
p-value 
Oral Cavity 
HRs (95% CIs) 
p-value 
Oropharynx 
HRs  
(95% CIs) 
p-value 
Hypopharynx 
HRs  
(95% CIs) 
p-value 
Number              
0-1 symptom 1.0 (REF.) 0.004 1.0 (REF.) 0.015 1.0 (REF.) 0.001 1.0 (REF.) 0.533 
2 symptoms 1.40 (1.01, 1.96)  1.32 (0.96, 1.80)   1.35 (0.94, 1.95)  1.15 (0.62, 2.15)  
3 symptoms 1.87 (1.28, 2.75)  1.88 (1.20, 2.95)   2.16 (1.44, 3.23)  1.45 (0.74, 2.83)  
Hoarseness           
Yes 0.80 (0.57, 1.12) 0.192 N/A* N/A* 1.88 (1.09, 3.22) 0.023 0.88 (0.53, 1.46) 0.613 
No 1.0 (REF.)  N/A* 
 
1.0 (REF.)  1.0 (REF.)  
Pain/discomfort           
Yes 1.21 (0.89, 1.65) 0.219 1.27 (0.95, 1.69) 0.106 1.42 (1.00, 2.02) 0.048 1.31 (0.79, 2.18) 0.303 
No 1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  
Lump in neck         
Yes 1.36 (0.84, 1.65) 0.214 1.78 (1.09, 2.91) 0.021 0.82 (0.55, 1.22) 0.320 0.77 (0.42, 1.43) 0.408 
No 1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  
Dysphagia         
Yes 1.01 (0.71, 1.46) 0.936 1.60 (1.03, 2.48) 0.037 1.57 (1.10, 2.25) 0.014 1.11 (0.68, 1.83) 0.670 
No 1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  
Ulceration             
Yes N/A*  N/A* 0.76 (0.57, 1.01) 0.060 1.28 (0.84, 1.93) 0.249 N/A* N/A* 
No N/A*   1.0 (REF.)  1.0 (REF.)  N/A*   
Weight loss             
Yes 1.90 (1.24, 2.92) 0.003 2.39 (1.47, 3.39) < 0.001 2.74 (1.73, 4.36) < 0.001 2.65 (1.55, 4.52) < 0.001 
No 1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  
Swelling             
Yes N/A* N/A* 1.02 (0.70, 1.49) 0.927 0.76 (0.46, 1.24) 0.269 N/A* N/A* 
No N/A*   1.0 (REF.)  1.0 (REF.)  N/A*   
Other/unknown             
Yes 1.64 (1.18, 2.27) 0.003 1.20 (0.90, 1.59) 0.212 1.09 (0.78, 1.53) 0.610 0.87 (0.52, 1.48) 0.618 
No 1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  1.0 (REF.)  
*Symptom included in “Other/unknown” due to low frequency of patients with the symptom for this anatomical site 
 
